Text Size

Clinical and Pathophysiological Description of Ocular Ischemic Syndrome

This study has been completed.
Sponsor:
Collaborators:
Rigshospitalet, Denmark
University Hospital, Gentofte, Copenhagen
Information provided by (Responsible Party):
Peter Kofoed, Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier:
NCT00403195
First received: November 21, 2006
Last updated: September 7, 2012
Last verified: September 2012
History of Changes
  Purpose

The purpose of this study is to characterize the disease Ocular Ischemic Syndrome.


Condition
Retinal Degeneration
Diabetic Retinopathy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Pathophysiological Analysis of Ocular Ischemic Syndrome and the Response to Vascular Surgery

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Glostrup University Hospital, Copenhagen:

Enrollment: 13
Study Start Date: November 2006
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Detailed Description:

The disease Ocular Ischemic Syndrome (OIS) is not a well described entity. It occurs after a long-standing period of extremely low blood supply to the retina caused by atherosclerosis of the carotid arteries. In this study we will analyze why OIS is developed in some patients and not developed in others. The patients with OIS will be thorough examined and will be compared with 1) a control group of healthy people and 2) with control group of patients with diabetic retinopathy. Furthermore the impact of vascular surgery on OIS will be analyzed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with the disease ocular ishemic syndrome. Patients will be screened through vascular surgery departments.

Criteria

Inclusion Criteria:

  • Ocular ischemic syndrome

Exclusion Criteria:

  • Any other active ocular disease
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00403195

Locations
Denmark
Department of Ophthalmology, Glostrup Hospital, University of Copenhagen
Glostrup, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Rigshospitalet, Denmark
University Hospital, Gentofte, Copenhagen
Investigators
Study Director: Michael Larsen, Professor
  More Information

No publications provided

Responsible Party: Peter Kofoed, Principal investigator, Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier: NCT00403195     History of Changes
Other Study ID Numbers: OIS
Study First Received: November 21, 2006
Last Updated: September 7, 2012
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics

Keywords provided by Glostrup University Hospital, Copenhagen:
Ocular Ischemic Syndrome

Additional relevant MeSH terms:
Diabetic Retinopathy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
 Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 19, 2013